From step Counters to Clinical Tools: How Wearables Are Maturing into VBC Infrastructure

As VBC continues to gain traction, the role of biometric wearables is transforming. What began as consumer tech is ๐˜ฃ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ช๐˜ฏ๐˜จ ๐˜ง๐˜ฐ๐˜ถ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ข๐˜ญ ๐˜ต๐˜ฐ ๐˜ณ๐˜ช๐˜ด๐˜ฌ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ค๐˜ข๐˜ณ๐˜ฆ ๐˜ฎ๐˜ฐ๐˜ฅ๐˜ฆ๐˜ญ๐˜ด.

Wearables are now being integrated into clinical protocols for:

โ–ช๏ธ Chronic disease management

โ–ช๏ธ Behavioral health

โ–ช๏ธ Post-acute monitoring

โ–ช๏ธ Decentralized trials

They provide continuous, passive data capture that supports proactive intervention. Traditional episodic care lacks this kind of real-time visibility, which is increasingly critical to reducing utilization, improving adherence, and enhancing outcomes under VBC contracts.

HHS has signaled that real-time patient monitoring is a national priority, given its potential to improve health outcomes and support care delivery in both rural and underserved settings.

For early-stage companies, expectations now require:

Clinical validation

EMR integration

Scalable patient engagement

Reimbursement readiness

Strategics and investors focus on platforms that align with value-based economics and can demonstrate measurable impact on cost and quality.

At our firm, we view this convergence as one of the most investable areas in healthcare innovation. If you're a founder building sensing and monitoring platforms, we would welcome a conversation.

Previous
Previous

FDA Policy Shift: Implications for MedTech & Diagnostics

Next
Next

DealScape | AI in Medtech